相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Topotecan or other agents as second‑line therapy for relapsed small‑cell lung cancer: A meta‑analysis of randomized studies
Fausto Petrelli et al.
Molecular and Clinical Oncology (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
D. R. Spigel et al.
ANNALS OF ONCOLOGY (2021)
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Luckson Mathieu et al.
ONCOLOGIST (2021)
Pathology and Classification of SCLC
Maria Gabriela Raso et al.
CANCERS (2021)
Reframing recalcitrance for small-cell lung cancer
F. H. Blackhall
ANNALS OF ONCOLOGY (2021)
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
Jared Weiss et al.
CLINICAL LUNG CANCER (2021)
Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2021)
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Renata Ferrarotto et al.
CANCER MEDICINE (2021)
Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies
Nicholas R. Liguori et al.
FRONTIERS IN PHARMACOLOGY (2021)
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56
Rie Sakakibara et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?
Andrew M. Bellizzi
HUMAN PATHOLOGY (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients
Damian von Eiff et al.
JOURNAL OF THORACIC DISEASE (2020)
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Kartik Sehgal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize et al.
LANCET ONCOLOGY (2020)
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah et al.
LUNG CANCER (2020)
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer
Sam T. Keeping et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
Marianna Christodoulou et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing
Shan Su et al.
Biomed Research International (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations
Natasha Rekhtman et al.
MODERN PATHOLOGY (2018)
Usage of Prophylactic Cranial Irradiation in Elderly Patients With Small-cell Lung Cancer
Ronald A. M. Damhuis et al.
CLINICAL LUNG CANCER (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database
Yoshiyuki Shioyama et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
Combined small-cell lung carcinoma
Jing Qin et al.
ONCOTARGETS AND THERAPY (2018)
Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening
Anish Thomas et al.
CHEST (2018)
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi et al.
MODERN PATHOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
M Reck et al.
ANNALS OF ONCOLOGY (2018)
Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer
Chi-Fu Jeffrey Yang et al.
ANNALS OF SURGERY (2018)
Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer
Vivek Verma et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)
Shadia I. Jalal et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases
Erik Thunnissen et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit?
Ahsan S. Farooqi et al.
RADIOTHERAPY AND ONCOLOGY (2017)
A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
Thierry Berghmans et al.
FRONTIERS IN ONCOLOGY (2017)
Management of Recurrent Small Cell Lung Cancer
Bryan J. Schneider
Journal of the National Comprehensive Cancer Network (2017)
NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
Donald A. Podoloff et al.
Journal of the National Comprehensive Cancer Network (2017)
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events
Marianne Davies et al.
IMMUNOTARGETS AND THERAPY (2017)
INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity
Lisa M. Rooper et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
Benjamin H. Lok et al.
ADVANCES IN RADIATION ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
Matthew David Hellmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
Koichi Goto et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Leora Horn et al.
ONCOLOGIST (2016)
Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients
Laura A. Hatfield et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question
Cesare Gridelli et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2016)
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial
J. -L. Pujol et al.
ANNALS OF ONCOLOGY (2015)
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience
Roberto Petrioli et al.
CLINICAL LUNG CANCER (2015)
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis
Giovenzio Genestreti et al.
CLINICAL LUNG CANCER (2015)
Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer
Christopher D. Corso et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Pulmonary neuroendocrine tumors in the new WHO 2015 classification. Start of breaking new grounds?
P. A. Schnabel et al.
PATHOLOGE (2015)
Grading the neuroendocrine tumors of the lung: an evidence-based proposal
G. Rindi et al.
ENDOCRINE-RELATED CANCER (2014)
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
Joachim von Pawel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
Philip E. Lammers et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
Marjorie G. Zauderer et al.
LUNG CANCER (2014)
Molecular profiling of small cell lung cancer in a Japanese cohort
Kazushige Wakuda et al.
LUNG CANCER (2014)
Pathology and Diagnosis of Neuroendocrine Tumors: Lung Neuroendocrine
William D. Travis
THORACIC SURGERY CLINICS (2014)
Establishing the Diagnosis of Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
M. Patricia Rivera et al.
CHEST (2013)
Treatment of Tobacco Use in Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Frank T. Leone et al.
CHEST (2013)
Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
James R. Jett et al.
CHEST (2013)
Modern Staging of Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Duration of Chemotherapy for Small Cell Lung Cancer: A Meta-Analysis
Hang Zhou et al.
PLOS ONE (2013)
Timing of failure in limited disease (stage I-III) small-cell lung cancer patients treated with chemoradiotherapy: a retrospective analysis
Farkhad Manapov et al.
TUMORI (2013)
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine- DNA Methyltransferase as a Potential Biomarker
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2012)
Cigarette smoking and lung cancerurelative risk estimates for the major histological types from a pooled analysis of case-control studies
Beate Pesch et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy
Nobuhiro Asai et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2012)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Diagnosis and Management of Hyponatremia in Cancer Patients
Jorge J. Castillo et al.
ONCOLOGIST (2012)
Staging and imaging of small cell lung cancer
Gregory P. Kalemkerian
CANCER IMAGING (2012)
Expression of Squamous Cell Carcinoma Markers and Adenocarcinoma Markers in Primary Pulmonary Neuroendocrine Carcinomas
Kyohei Masai et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2012)
Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)
C. Le Pechoux et al.
ANNALS OF ONCOLOGY (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
Robert Jotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers
Sinead Cuffe et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
Meleeneh Kazarian et al.
MOLECULAR CANCER (2011)
Different efficacy of CT screening for lung cancer according to histological type: Analysis of Japanese-smoker cases detected using a low-dose CT screen
Ryoichi Kondo et al.
LUNG CANCER (2011)
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
Denise R. Aberle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Advances in the Treatment of Small-Cell Lung Cancer
Gregory P. Kalemkerian
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
I. K. Demedts et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer Systematic Review with Meta-Analysis
Joao Paulo S. N. Lima et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer
James B. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms
Thomas E. Stinchcombe et al.
ONCOLOGIST (2010)
Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis
A. Parsons et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Prognostic Factors Differ by Tumor Stage for Small Cell Lung Cancer A Pooled Analysis of North Central Cancer Treatment Group Trials
Nathan R. Foster et al.
CANCER (2009)
Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy
Andrew R. L. Medford et al.
CURRENT OPINION IN PULMONARY MEDICINE (2009)
Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer
Tsuneo Shimokawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes-an International Multi-Centre Experience
Robert C. Rintoul et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
Jane L. Hurwitz et al.
ONCOLOGIST (2009)
Detection of brain metastases from small cell lung cancer - Consequences of changing imaging techniques (CT versus MRI)
Tatjana Seute et al.
CANCER (2008)
Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study
Joseph G. Verbalis et al.
CLINICAL ENDOCRINOLOGY (2008)
Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome
Maarten J. Titulaer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer:: A Randomized phase III trial
Andreas Hermes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
H. Okamoto et al.
BRITISH JOURNAL OF CANCER (2007)
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer
Chirag Shah et al.
LUNG CANCER (2007)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemotherapy for relapsed small cell lung cancer: A systematic review and practice guideline
Susanna Cheng et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis
B. M. Fischer et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic oncology research group study 0301
Sayaka Onoda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
Robert W. Schrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer
RM Huber et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732
HB Niell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens - A major pitfall in the management of lung cancer patients
G Pelosi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Positron emission tomography in limited-stage small-cell lung cancer: A prospective study
JD Bradley et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer
I Brink et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Small-cell carcinomas of the gastrointestinal tract: A review
B Brenner et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with eastern cooperative oncology group performance status of 2, or age ≥ 70 years
M Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival
GMM Videtic et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern cooperative oncology group trial 1597
GA Masters et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pathology of small cell carcinoma of the lung
MF Zakowski
SEMINARS IN ONCOLOGY (2003)
Management of lung cancer in older adults
A Hurria et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2003)
Small cell lung carcinoma (SCLC) - A clinicopathologic study of 100 cases with surgical specimens
SA Nicholson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Staging small cell lung cancer: Veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease?
P Micke et al.
LUNG CANCER (2002)
Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis
T Berghmans et al.
LUNG CANCER (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
JP Sculier et al.
BRITISH JOURNAL OF CANCER (2001)
Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer
K Matsui et al.
INTERNAL MEDICINE (2001)
Anti-Hu-associated paraneoplastic encephalomyelitis:: analysis of 200 patients
F Graus et al.
BRAIN (2001)
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group
JH Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer:: A French federation of cancer institutes multicenter phase III randomized study
JL Pujol et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas
NG Ordonez
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)
分享论文
